UNSPSC 51342712: Peginterferon alfa-2b

This classification denotes a pegylated interferon alfa with the molecular formula C2H4NO2(C2H4O)N, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier G8RGG88B68. European Medicines Agency schedules peginterferon alfa-2b in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12549MIG. The term PEGINTERFERON ALFA-2B is an International Non-Proprietary Name or INN.

UNSPSC 51342712 Peginterferon alfa-2b is a Commodity code representing pharmaceutical products that state and local governments procure for public health programs and emergency response initiatives. Recent state and local opportunities under this code show minimal direct alignment with the nominal product scope; the recorded solicitations instead reflect broader pharmaceutical procurement patterns driven by immediate public health needs rather than peginterferon alfa-2b specifically. State and local issuing bodies soliciting pharmaceutical supplies through this code tier include state health departments and county governments, with procurement vehicles often structured as piggyback awards through established pharmaceutical consortia or cooperative purchasing frameworks to accelerate delivery and reduce administrative overhead.

The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract to Chartwell Rx LLC on August 28, 2026, through the MMCAP Infuse consortium for antibiotic supplies (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) with a total award value of $2,999,999.11 over three years. Seminole County, Florida issued an IFB on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building, under a two-year initial term with one-year renewal option. Recent activity concentrates in Florida and Illinois, with procurement driven by pharmaceutical supply chains supporting communicable disease response and overdose-reversal initiatives. The code shows sparse direct activity; opportunities recorded under the peginterferon alfa-2b designation do not substantiate active state and local demand for that specific therapeutic agent at scale.